echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JAMA Sub-Journal: The relationship between SGLT2 inhibitors and the incidence of type 2 diabetes and gout

    JAMA Sub-Journal: The relationship between SGLT2 inhibitors and the incidence of type 2 diabetes and gout

    • Last Update: 2021-12-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Sodium - glucose transporter (the SGLT2) 2 using an inhibitor is 2 type diabetes mellitus (T2DM) standard interventions the patient has good pleiotropic effects on lowering blood uric acid levels continued
    .


    However, so far, there are few studies on the association between the use of SGLT2 inhibitors and the incidence of gout


    Sodium - glucose transporter (the SGLT2) 2 using an inhibitor is 2 type Diabetes diabetes (T2DM) standard interventions the patient has good pleiotropic effects on lowering blood uric acid levels continued


    This retrospective cohort study analyzed 2016 Nian 5 Yue 1 to 2018 Nian 12 Yue 31 all occurred between Taiwan health authorities database date in T2DM patients
    .


    As a control, patients using dipeptidyl peptidase 4 ( DPP4 ) inhibitors were included


    This retrospective cohort study analyzed 2016 Nian 5 Yue 1 to 2018 Nian 12 Yue 31 all occurred between Taiwan health authorities database date in T2DM patients


    A total of 231208 Ming 2 diabetes patients with type into the crowd, 113,812 people ( 49.


    The incidence of gout in type 2 diabetic patients receiving dipeptidyl peptidase 4 (DPP4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors

    The incidence of gout in type 2 diabetic patients receiving dipeptidyl peptidase 4 (DPP4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors

    When using ICD-9-CM or ICD-10-CM codes and gout-related drugs to determine the diagnosis of gout , the sensitivity analysis also showed that the incidence of gout with SGLT2 inhibitors was significantly reduced by 15% ( HR , 0.
    85 ; 95%) CI , 0.
    74-0.
    97 )
    .


    Subgroup analysis showed that the benefits of SGLT2 inhibitors in reducing the risk of gout in T2DM patients did not differ among the subgroups


    When using ICD-9-CM or ICD-10-CM codes and gout-related drugs to determine the diagnosis of gout , sensitivity analysis also showed that the incidence of gout using diagnostic SGLT2 inhibitors was significantly reduced by 15% ( HR , 0.


    Incidence and risk of gout in patients with type 2 diabetes with DPP4 and SGLT2 inhibitors

    Incidence and risk of gout in patients with type 2 diabetes with DPP4 and SGLT2 inhibitors

    The results of this study showed that patients with T2DM who received SGLT2 inhibitors had a lower risk of gout compared with patients with T2DM who received DPP4 inhibitors
    .

    The results of this study indicate that the acceptance and acceptance and acceptance compared to T2DM patients DPP4 inhibitors, SGLT2 inhibitors to accept lower risk of T2DM patients suffering from gout
    .


    Compared with T2DM patients who received DPP4 inhibitors, T2DM patients who received SGLT2 inhibitors had a lower risk of gout


    Chung M, Hung P, Hsiao P, et al.
    Association of Sodium-Glucose Transport Protein 2 Inhibitor Use for Type 2 Diabetes and Incidence of Gout in Taiwan.
    JAMA Netw Open.
    JAMA2021;4(11):e2135353.
    doi:10.
    1001 /jamanetworkopen.
    2021.
    35353 doi:10.
    1001/jamanetworkopen.
    2021.
    35353 leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.